Xerostomia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type (OTC and Prescription), Product, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Description

List of Tables

The xerostomia therapeutics market size is expected to reach USD 2,993.61 million by 2034, according to a new study by Polaris Market Research. The report "Xerostomia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Type (OTC and Prescription), Product, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The xerostomia therapeutics market focuses on products designed to manage dry mouth, a condition where the salivary glands do not produce enough saliva, leading to discomfort and potential oral health issues. The market includes salivary stimulants, substitutes, and oral care products aimed at relieving symptoms and improving oral health. The xerostomia therapeutics market growth is driven by factors such as an aging population, increasing awareness about xerostomia, and the rising prevalence of conditions such as Sjogren's syndrome and side effects from medications.

Xerostomia therapeutics market opportunities lie in the development of more effective and personalized treatments, with advancements in salivary stimulants and substitutes. Trends include the growing demand for over-the-counter solutions, innovations in oral healthcare products, and the expanding use of digital marketing strategies. Overall, the market demand is expected to grow steadily during the forecast period, fueled by the increasing number of affected individuals, the development of advanced treatment options, and the expanding awareness globally.

Xerostomia Therapeutics Market Report Highlights

The OTC segment, based on type, dominated the xerostomia therapeutics market share in 2024 due to the widespread availability and affordability of products, offering quick relief for dry mouth symptoms. However, the prescription segment is registering the fastest growth, driven by increasing cases of chronic conditions such as Sjogren's syndrome that require specialized treatments.
The salivary stimulants segment, by product, dominated the market share in 2024 as they are effective in stimulating saliva production, addressing the core issue of xerostomia.
North America dominated the xerostomia therapeutics market revenue share in 2024 due to the high prevalence of xerostomia and extensive healthcare access. Asia Pacific is the fastest growing due to increasing awareness of the condition, rising healthcare infrastructure, and a growing elderly population.
The market comprises several active companies offering various treatments for dry mouth. A few notable participants include Acacia Pharma; Church & Dwight Co., Inc.; Colgate-Palmolive Company; Forward Science; GlaxoSmithKline plc; Hikma Pharmaceuticals PLC; Lupin Pharmaceuticals, Inc.; Mission Pharmacal Company; OraCoat; Parnell Pharmaceuticals, Inc.; Pendopharm; Pfizer Inc.; Recordati Industria Chimica e Farmaceutica S.p.A; Sun Pharmaceutical Industries Ltd.; and Synedgen, Inc.

Polaris Market Research has segmented the xerostomia therapeutics market report on the basis of type, product, and region:

By Type Outlook (Revenue - USD Million, 2020-2034)

OTC
Prescription

By Product Outlook (Revenue - USD Million, 2020-2034)

Salivary Stimulants
Salivary Substitutes
Dentifrices

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM1339

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Xerostomia Therapeutics Market Insights

4.1. Xerostomia Therapeutics Market - Market Snapshot
4.2. Xerostomia Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.2. Restraints and Challenges
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Xerostomia Therapeutics Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Xerostomia Therapeutics Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
5.3. OTC
- 5.3.1. Global Xerostomia Therapeutics Market, by OTC, by Region, 2020-2034 (USD Million)
5.4. Prescription
- 5.4.1. Global Xerostomia Therapeutics Market, by Prescription, by Region, 2020-2034 (USD Million)

6. Global Xerostomia Therapeutics Market, by Product

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
6.3. Salivary Stimulants
- 6.3.1. Global Xerostomia Therapeutics Market, by Salivary Stimulants, by Region, 2020-2034 (USD Million)
6.4. Salivary Substitutes
- 6.4.1. Global Xerostomia Therapeutics Market, by Specialty Clinics, by Region, 2020-2034 (USD Million)
6.5. Dentifrices
- 6.5.1. Global Xerostomia Therapeutics Market, by Dentifrices, by Region, 2020-2034 (USD Million)

7. Global Xerostomia Therapeutics Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Xerostomia Therapeutics Market Assessment, By Geography, 2020-2034 (USD Million)
7.3. Xerostomia Therapeutics Market - North America
- 7.3.1. North America: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
- 7.3.2. North America: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.3.3. Xerostomia Therapeutics Market - U.S.
  - 7.3.3.1. U.S.: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.3.3.2. U.S.: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.3.4. Xerostomia Therapeutics Market - Canada
  - 7.3.4.1. Canada: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.3.4.2. Canada: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
7.4. Xerostomia Therapeutics Market - Europe
- 7.4.1. Europe: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
- 7.4.2. Europe: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.3. Xerostomia Therapeutics Market - UK
  - 7.4.3.1. UK: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.4.3.2. UK: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.4. Xerostomia Therapeutics Market - France
  - 7.4.4.1. France: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.4.4.2. France: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.5. Xerostomia Therapeutics Market - Germany
  - 7.4.5.1. Germany: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.4.5.2. Germany: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.6. Xerostomia Therapeutics Market - Italy
  - 7.4.6.1. Italy: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.4.6.2. Italy: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.7. Xerostomia Therapeutics Market - Spain
  - 7.4.7.1. Spain: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.4.7.2. Spain: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.8. Xerostomia Therapeutics Market - Netherlands
  - 7.4.8.1. Netherlands: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.4.8.2. Netherlands: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.9. Xerostomia Therapeutics Market - Russia
  - 7.4.9.1. Russia: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.4.9.2. Russia: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.4.10. Xerostomia Therapeutics Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.4.10.2. Rest of Europe: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
7.5. Xerostomia Therapeutics Market - Asia Pacific
- 7.5.1. Asia Pacific: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.3. Xerostomia Therapeutics Market - China
  - 7.5.3.1. China: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.5.3.2. China: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.4. Xerostomia Therapeutics Market - India
  - 7.5.4.1. India: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.5.4.2. India: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.5. Xerostomia Therapeutics Market - Malaysia
  - 7.5.5.1. Malaysia: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.5.5.2. Malaysia: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.6. Xerostomia Therapeutics Market - Japan
  - 7.5.6.1. Japan: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.5.6.2. Japan: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.7. Xerostomia Therapeutics Market - Indonesia
  - 7.5.7.1. Indonesia: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.5.7.2. Indonesia: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.8. Xerostomia Therapeutics Market - South Korea
  - 7.5.8.1. South Korea: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.5.8.2. South Korea: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.9. Xerostomia Therapeutics Market - Australia
  - 7.5.9.1. Australia: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.5.9.2. Australia: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.5.10. Xerostomia Therapeutics Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.5.10.2. Rest of Asia Pacific: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
7.6. Xerostomia Therapeutics Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.3. Xerostomia Therapeutics Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.6.3.2. Saudi Arabia: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.4. Xerostomia Therapeutics Market - UAE
  - 7.6.4.1. UAE: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.6.4.2. UAE: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.5. Xerostomia Therapeutics Market - Israel
  - 7.6.5.1. Israel: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.6.5.2. Israel: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.6. Xerostomia Therapeutics Market - South Africa
  - 7.6.6.1. South Africa: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.6.6.2. South Africa: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.6.7. Xerostomia Therapeutics Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.6.7.2. Rest of Middle East & Africa: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
7.7. Xerostomia Therapeutics Market - Latin America
- 7.7.1. Latin America: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
- 7.7.2. Latin America: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.7.3. Xerostomia Therapeutics Market - Mexico
  - 7.7.3.1. Mexico: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.7.3.2. Mexico: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.7.4. Xerostomia Therapeutics Market - Brazil
  - 7.7.4.1. Brazil: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.7.4.2. Brazil: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.7.5. Xerostomia Therapeutics Market - Argentina
  - 7.7.5.1. Argentina: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.7.5.2. Argentina: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)
- 7.7.6. Xerostomia Therapeutics Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Xerostomia Therapeutics Market, by Type, 2020-2034 (USD Million)
  - 7.7.6.2. Rest of Latin America: Xerostomia Therapeutics Market, by Product, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. GlaxoSmithKline plc
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Church & Dwight Co., Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Colgate-Palmolive Company
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Hikma Pharmaceuticals PLC
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Pendopharm
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Sun Pharmaceutical Industries Ltd
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Lupin Pharmaceuticals, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Pfizer Inc.
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Parnell Pharmaceuticals, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Acacia Pharma
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development